|
1
|
Smolen JS, Landewé R, Bijlsma J, Burmester
G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van
Vollenhoven R, et al: EULAR recommendations for the management of
rheumatoid arthritis with synthetic and biological
disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis.
76:960–977. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Baecklund E, Iliadou A, Askling J, Ekbom
A, Backlin C, Granath F, Catrina AI, Rosenquist R, Feltelius N,
Sundström C, et al: Association of chronic inflammation, not its
treatment, with increased lymphoma risk in rheumatoid arthritis.
Arthritis Rheum. 54:692–701. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ellman MH, Hurwitz H, Thomas C and Kozloff
M: Lymphoma developing in a patient with rheumatoid arthritis
taking low dose weekly methotrexate. J Rheumatol. 18:1741–1743.
1991.PubMed/NCBI
|
|
4
|
Ishiguro K, Hayashi T, Aoki Y, Murakami R,
Ikeda H and Ishida T: Other iatrogenic immunodeficiency-associated
lymphoproliferative disorder presenting as primary bone lymphoma in
a patient with rheumatoid arthritis. Intern Med. 55:2259–2264.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kameda T, Dobashi H, Miyatake N, Inoo M,
Onishi I, Kurata N, Mitsunaka H, Kawakami K, Fukumoto T, Susaki K,
et al: Association of higher methotrexate dose with
lymphoproliferative disease onset in rheumatoid arthritis patients.
Arthritis Care Res (Hoboken). 66:1302–1309. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hoshida Y, Xu JX, Fujita S, Nakamichi I,
Ikeda J, Tomita Y, Nakatsuka S, Tamaru J, Iizuka A, Takeuchi T, et
al: Lymphoproliferative disorders in rheumatoid arthritis:
Clinicopathological analysis of 76 cases in relation to
methotrexate medication. J Rheumatol. 34:322–331. 2007.PubMed/NCBI
|
|
7
|
Miyazaki T, Fujimaki K, Shirasugi Y,
Yoshiba F, Ohsaka M, Miyazaki K, Yamazaki E, Sakai R, Tamaru J,
Kishi K, et al: Remission of lymphoma after withdrawal of
methotrexate in rheumatoid arthritis: Relationship with type of
latent Epstein-Barr virus infection. Am J Hematol. 82:1106–1109.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mariette X, Cazals-Hatem D, Warszawki J,
Liote F, Balandraud N and Sibilia J; Investigators of the Club
Rhumatismes et Inflammation, : Lymphomas in rheumatoid arthritis
patients treated with methotrexate: A 3-year prospective study in
France. Blood. 99:3909–3915. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Matsuda K, Gotoh M, Mitsui Y, Yoshikawa E,
Kume S, Yano M, Honda S, Okawa T, Fukuda T, Higuchi F, et al:
Steinbrocker classification class IV to class II after multi-joint
surgery. Kurume Med J. 59(7): 9–82. 2012.10.
|
|
10
|
Lu DR, McDavid AN, Kongpachith S,
Lingampalli N, Glanville J, Ju CH, Gottardo R and Robinson WH: T
cell-dependent affinity maturation and innate immune pathways
differentially drive autoreactive B cell responses in rheumatoid
arthritis. Arthritis Rheumatol. May 31–2018.(Epub ahead of print).
View Article : Google Scholar
|
|
11
|
Mokuda S, Miyazaki T, Saeki Y, Masumoto J,
Kanno M and Takasugi K: Epstein-Barr virus-related MTX-LPD in
rheumatoid arthritis patients exhibits a viral pattern of the CD64
and CD35 expression on neutrophils: Three case reports. Mod
Rheumatol. 25:166–168. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tokuhira M, Watanabe R, Nemoto T, Sagawa
M, Tomikawa T, Tamaru J, Itoyama S, Nagasawa H, Amano K, Kameda H,
et al: Clinicopathological analyses in patients with other
iatrogenic immunodeficiency-associated lymphoproliferative diseases
and rheumatoid arthritis. Leuk Lymphoma. 53:616–623. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hashimoto A, Chiba N, Tsuno H, Komiya A,
Furukawa H, Matsui T, Nishino J and Tohma S: Incidence of
malignancy and the risk of lymphoma in Japanese patients with
rheumatoid arthritis compared to the general population. J
Rheumatol. 42:564–571. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ureshino H, Kadota C, Kurogi K, Miyahara M
and Kimura S: Spontaneous Regression of Methotrexate-related
Lymphoproliferative Disorder with T-cell Large Granular
Lymphocytosis. Intern Med. 54:2235–2239. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ichikawa A, Arakawa F, Kiyasu J, Sato K,
Miyoshi H, Niino D, Kimura Y, Takeuchi M, Yoshida M, Ishibashi Y,
et al: Methotrexate/iatrogenic lymphoproliferative disorders in
rheumatoid arthritis: Histology, Epstein-Barr virus, and clonality
are important predictors of disease progression and regression. Eur
J Haematol. 91:20–28. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Katsuyama T, Sada KE, Yan M, Zeggar S,
Hiramatsu S, Miyawaki Y, Ohashi K, Morishita M, Watanabe H,
Katsuyama E, et al: Prognostic factors of methotrexate-associated
lymphoproliferative disorders associated with rheumatoid arthritis
and plausible application of biological agents. Mod Rheumatol.
27:773–777. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zaidi A, Kampalath B, Peltier WL and
Vesole DH: Successful treatment of systemic and central nervous
system lymphomatoid granulomatosis with rituximab. Leuk Lymphoma.
45:777–780. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gion Y, Iwaki N, Takata K, Takeuchi M,
Nishida K, Orita Y, Tachibana T, Yoshino T and Sato Y:
Clinicopathological analysis of methotrexate-associated
lymphoproliferative disorders: Comparison of diffuse large B-cell
lymphoma and classical Hodgkin lymphoma types. Cancer Sci.
108:1271–1280. 2017. View Article : Google Scholar : PubMed/NCBI
|
